TTHI Share Price

Open 1.54 Change Price %
High 1.57 1 Day 0.00 0.00
Low 1.52 1 Week 0.00 0.00
Close 1.52 1 Month 0.00 0.00
Volume 12424 1 Year 0.60 65.22
52 Week High 1.70
52 Week Low 0.66
TTHI Important Levels
Resistance 2 1.57
Resistance 1 1.55
Pivot 1.54
Support 1 1.49
Support 2 1.47
NASDAQ USA Most Active Stocks
NVDA 100.49 -9.27%
JBHT 97.31 -1.05%
AREX 2.96 -1.99%
OZRK 55.54 1.02%
FNSR 34.15 0.12%
AGNC 19.64 0.72%
EA 86.65 -0.84%
FNFG 10.18 -0.20%
PRFZ 118.04 -0.80%
DELL 13.86 0.22%
More..
NASDAQ USA Top Gainers Stocks
ECTE 0.18 50.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
ZAZA 0.06 20.00%
JAKK 5.70 12.87%
LINE 0.18 12.50%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Transition Therapeutics, Inc. (NASDAQ: TTHI)

TTHI Technical Analysis 4
As on 30th Aug 2016 TTHI Share Price closed @ 1.52 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.37 & Strong Buy for SHORT-TERM with Stoploss of 1.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
TTHI Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TTHI Other Details
Segment EQ
Market Capital 60303716.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transitiontherapeutics.com
TTHI Address
TTHI
101 College Street
Suite 220
Toronto, ON M5G 1L7
Canada
Phone: 416-260-7770
TTHI Latest News
The Synergy From OPKO's Acquisition of Transition Therapeutics (OPK)   Investopedia   - 15th Sep 16
OPKO Health Completes Acquisition of Transition Therapeutics   Business Wire (press release)   - 31st Aug 16
OPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder ...   StreetInsider.com   - 26th Aug 16
OPKO Health to Acquire Transition Therapeutics   Business Wire (press release)   - 30th Jun 16
Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of ...   PR Newswire (press release)   - 01st Feb 16
Eli Lilly Can Save Transition Therapeutics Inc.   Seeking Alpha   - 30th Dec 15
Transition Therapeutics Announces Agreement for Phase 2 Study of TT701 Drug ...   PR Newswire (press release)   - 30th Oct 15
Transition Therapeutics Inc. (TTHI) Stock | Results of Data Analysis from ...   Warrior Trading News (press release)   - 17th Oct 15
Transition Therapeutics Announces Results of Clinical Study of ELND005 in ...   PR Newswire (press release)   - 24th Jun 15
Transition Therapeutics In-Licenses Phase 2 Drug Candidate from Lilly   PR Newswire (press release)   - 06th May 15
Interactive Technical Analysis Chart Transition Therapeutics, Inc. ( TTHI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transition Therapeutics, Inc.
TTHI Business Profile
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with large markets. The Company�s s technologies in development are ELND005 (AZD-103) for the treatment of Alzheimer�s disease and bipolar disorder; TT-401/402 for the treatment of diabetes ,and TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, neuropathic pain, Alzheimer�s disease, traumatic brain injury and intracerebral haemorrhage. The Company has one wholly owned material subsidiary, Waratah Pharmaceuticals Inc. (Waratah), which is engaged in the development and commercialization of its ELND005 (AZD-103); the type II diabetes drug candidate TT-401; and TT-301 and TT-302.